360° SearchNetwork Hot Spots Trends Time Series

Lipase

Type: Keyphrase

Name: Lipase

First reported 9 hours ago - Updated 7 hours ago - 1 reports

3 Horrendous Health-Care Stocks This Week

Keep track of the stocks that matter to you.Help yourself with the Fool's FREE and easy new watchlist service today.There's one drawback to having the stock market indexes hit record highs yet again: It makes finding truly horrendous health-care stocks ... [Published Motley Fool - 9 hours ago]

Entities: watchlist, Drugs, Oncothyreon Inc, Lung Cancer, Infinity Pharmaceuticals Inc

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Development and Scale up of High-Yield Crystallization Processes of Lysozyme and Lipase Using Additives

Compared to standard protein formulations like aqueous solutions, crystalline proteins may offer superior properties (e.g., higher purity and concentration, reduced storage costs, and enhanced shelf life). In this work, crystallization conditions for ... [Published Crystal Growth & Design - May 17 2013]

Entities: Lipase, Lysozyme, Protein

First reported May 16 2013 - Updated May 16 2013 - 2 reports

WATCH: The Story Behind Glybera Approval

Late last year the European Medicines Agency (EMEA) granted marketing approval for the Western world’s first gene therapy product, Glybera, which is intended for the treatment of lipoprotein lipase deficiency, a rare inherited disease. The EMEA approval ... [Published Genetic Engineering News - May 16 2013]

Entities: Glybera, Human Gene Therapy, Gene Therapy

First reported May 15 2013 - Updated May 15 2013 - 1 reports

University of Liège

Study Results from University of Liege in the Area of Carbox. . .

Study Results from University of Liege in the Area of Carboxylic Ester Hydrolases ReportedEnzymes and CoenzymesNewsRx.comBy a News Reporter-Staff News Editor at Life Science Weekly -- A new study on Enzymes and Coenzymes is now available. According to ... [Published Equities.com - May 15 2013]

Entities: University of Liège, Cation, Anion, Enzymes

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Marijuana Hedge Fund Launches Edibles

New York (HedgeCo.Net) – Latteno Food Corp.’s wholly-owned subsidiary Green Cannabis, has rolled-out it’s first set of medical marijuana edible products consisting of Peanut Butter Cups, Chocolate Bars and Chocolate Chip Cookies all made out of Cann ... [Published HedgeCo - May 15 2013]

Entities: Hedge Fund, Marijuana, Receptor

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Synthesis, Enantiomer Separation, and Absolute Configuration of 2,6-Oxygenated 9-Azabicyclo[3.3.1]nonanes

The synthesis of the enantiomerically pure N-Boc 9-azabicyclo[3.3.1]nonane-2,6-dione (4b), a potentially useful chiral building block, from N-Bn and N-Boc 9-azabicyclo[3.3.1]nonane-2,6-diols 2a and 2b was accomplished. The enantiomer resolution of diols ... [Published Journal of Organic Chemistry - May 14 2013]

Entities: Synthesis, Lipase

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Abdul Rashid

USM bags 13 gold, 2 silver at invention expo

INNOVATIVE: New method to tackle global oil spills among medal winnersGEORGE TOWN: UNIVERSITI Sains Malaysia (USM) recorded a 100 per cent medal haul at the recent International Invention, Innovation and Technology Exhibition (ITEX) 2013 in Kuala Lumpur, ... [Published New Straits Times - May 14 2013]

Entities: Invention, Mohamed Ismail, Abdul Rashid

First reported May 11 2013 - Updated May 11 2013 - 1 reports

Stand up to keep fit and healthy at work

The war against office desks is raging, with new research showing we increase our risks of heart disease with every hour we spend glued to our chairs.And exercise at the start or end of the day doesn't cut it - it's the movement we get during our work ... [Published stuff.co.nz - May 11 2013]

Entities: Heart Foundation of New Zealand, Cholesterol, Auckland University of Technology

First reported May 11 2013 - Updated May 11 2013 - 1 reports

The Complex Fate in Plasma of Gadolinium Incorporated into High-Density Lipoproteins Used for Magnetic Imaging of Atherosclerotic Plaques

We have previously reported enhancing the imaging of atherosclerotic plaques in mice using reconstituted high density lipoproteins (HDL) as nanocarriers for the MRI contrast agent gadolinium (Gd). This study focuses on the underlying mechanisms of Gd ... [Published Bioconjugate Chemistry - May 11 2013]

Entities: Lipoprotein, Gadolinium, In Vivo, Coronary Artery Disease

First reported May 09 2013 - Updated May 10 2013 - 2 reports

Cornerstone Therapeutics Reports First Quarter 2013 Financial Results

Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets, today announced results for the first quarter ended March 31, 2013.Total net product ... [Published Citybizlist - May 09 2013]

Entities: Cornerstone Therapeutics Inc, Patient, Curosurf, Pancreatic Enzyme

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Patent Application Titled "Enzymatic Process for Synthesizin. . .

Patent Application Titled "Enzymatic Process for Synthesizing Estolides" Published OnlinePetroleo Brasileiro S.a. - PetrobrasNewsRx.comBy a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., ... [Published Equities.com - May 08 2013]

Entities: Lipase, octadecanoic acid, lubricant, Ricinoleic Acid

First reported Apr 29 2013 - Updated Apr 29 2013 - 2 reports

The biology of fats in the body

When you have your cholesterol checked, the doctor typically gives you levels of three fats found in the blood: LDL, HDL and triglycerides. But did you know your body contains thousands of other types of fats, or lipids?In human plasma alone, researchers ... [Published Medical Xpress - Apr 29 2013]

Entities: Lipids, Triglycerides, Biology, Cholesterol, Protein

Quotes

"The further exploration of immunotherapy as standalone therapy without chemotherapy for a devastating disease such as advanced melanoma is a tremendous advance. We are identifying therapies that appear better together than alone and look promising for more than just a small subset of patients. The extensive tumor shrinkage that was observed in this study is exactly the type of benefit patients and doctors have been hoping for" said Dr. Sandra M Swain

Dual immunotherapy scores rapid response in metastatic melanoma [Published Oncology Report - May 16 2013]

...Hayden's laboratory to develop a gene replacement therapy. In the article "From Mutation Identification to Therapy: Discovery and Origins of the First Approved Gene Therapy in the Western World" the authors recount the many failures and successes and the significant delays that finally ended on November 2, 2012, when the European Medicines Agency...

Scientists reveal inside story of European regulatory review and approval of Glybera [Published News-Medical.Net - May 16 2013]

...settings," said Pablo Cagnoni, M D , Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."

ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceuticals Announces Data Presentations at 49th American So ... [Published 4 Traders - May 15 2013]

...types with high unmet medical need," said Pamela A Cyrus, MD, Vice President and Head of U S Medical Affairs, Bayer HealthCare Pharmaceuticals. "At this year's ASCO, data presentations on Bayer's products will highlight our continued commitment to making ongoing investments in areas where therapeutic options are very much needed." Sponsored by: Notable studies evaluating Bayer's oncology products and compounds at ASCO include:

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013 [Published TickerTech.com - May 15 2013]

More Content

sort by: Date \| Relevance
3 Horrendous Health-Care Stocks This Week [Published Motley Fool - 9 hours ago]
Development and Scale up of High-Yield Crystall... [Published Crystal Growth & Design - May 17 2013]
Dual immunotherapy scores rapid response in met... [Published Oncology Report - May 16 2013]
WATCH: The Story Behind Glybera Approval [Published Genetic Engineering News - May 16 2013]
Scientists reveal inside story of European regu... [Published News-Medical.Net - May 16 2013]
Medicinal Mushrooms: Natural Supplement for Dia... [Published Positive Health - May 16 2013]
Ed Burmeister [Published Ozaukee Press - May 16 2013]
ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceutical... [Published 4 Traders - May 15 2013]
Bayer to Present New Data Across Oncology Portf... [Published TickerTech.com - May 15 2013]
Study Results from University of Liege in the A... [Published Equities.com - May 15 2013]
The Inside Story Behind the Approval of the Gen... [Published Prlog - May 15 2013]
Marijuana Hedge Fund Launches Edibles [Published HedgeCo - May 15 2013]
Synageva BioPharma™ Joins the International MPS... [Published Business Wire - May 15 2013]
Exocrine Pancreatic Insufficiency: Can Cause Yo... [Published Mercola - May 15 2013]
Bayer Initiates Phase III Trial of Stivarga® (r... [Published Street Insider - May 15 2013]
uniQure raises EUR 14.1m in new investment led ... [Published Noodls - May 15 2013]
Latteno's Subsidiary Green Cannabis Introduces ... [Published TheStreet.com - May 14 2013]
Maria Rodale: Renew Your Vitality with a Spring... [Published Huffington Post - May 14 2013]
Synthesis, Enantiomer Separation, and Absolute ... [Published Journal of Organic Chemistry - May 14 2013]
Glue composition for lung volume reduction [Published PharmCast - May 14 2013]
Thermogenic Ingredients for Weight Management: ... [Published Nutritional Outlook - May 14 2013]
USM bags 13 gold, 2 silver at invention expo [Published New Straits Times - May 14 2013]
Synageva BioPharma Posts 1Q 2013 Financial Results [Published Individual.com - May 13 2013]
Stand up to keep fit and healthy at work [Published stuff.co.nz - May 11 2013]
The Complex Fate in Plasma of Gadolinium Incor... [Published Bioconjugate Chemistry - May 11 2013]
Profile of Bruce Beutler [Published Bio Techniques - May 10 2013]
Under the Microscope: Epiq Ripped [Published Flex Magazine - May 10 2013]
Cornerstone acquires US marketing rights to Per... [Published PharmaBiz - May 10 2013]
Cornerstone Therapeutics Management Discusses Q... [Published Seeking Alpha - May 09 2013]
3 Steps to Beat Belly Fat [Published Stack TV - May 09 2013]

Blogs

sort by: Date \| Relevance
Dear Mark: Cycling at Work, Refueling After Spr... [Published Mark's Daily Apple - Mar 25 2013] For today’s edition of Dear Mark , I’m tackling four questions. First, I discuss the negative effects of sitting and explore whether stationary cycling as you work can mitigate the bad stuff associated with sitting for too long. Next, I explore how ...
Orphan designation: Recombinant human bile salt... [Published Orphan designations - Mar 20 2013]
Orphan designation: Recombinant microbial lipas... [Published Orphan designations - Mar 01 2013]
4 Healthcare Stock Stories for Tuesday Wellness [Published Wall St. Cheat Sheet - Feb 12 2013] Sanofi-Aventis ( NYSE:SNY ): Closing price $48.90 On Monday, Regeneron Pharmaceuticals reported that it was notifiied by Sanofi under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 that it plans to buy common stock of Regeneron via open ...
Still Waiting For A Biotech Revolution [Published FuturePundit - Dec 23 2012] The first attempts at human gene therapy were made in 1990. The excitement around gene therapy was high in the 1990s. Yet not till 22 years later in 2012 the first gene therapy drug, Glybera for a rare genetic disease called lipoprotein lipase deficiency, ...

Press Releases

sort by: Date \| Relevance
Synageva BioPharma™ Joins the International MPS... [Published Business Wire - May 15 2013]
Synageva BioPharma™ Announces One Year of Treat... [Published Business Wire Health News - May 09 2013]
Synageva BioPharma™ Reports First Quarter 2013 ... [Published Business Wire - May 07 2013]
Synageva BioPharma™ Initiates Dosing in Phase 3... [Published EON Health & Medicine - Feb 11 2013]
Synageva BioPharma™ Initiates Dosing in Phase 3... [Published Business Wire Health News - Feb 11 2013]